Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Blandine Ligneau"'
Autor:
Blandine Ligneau, Jean Leprêtre, Jean-Christophe Saurin, Bertrand Napoleon, Annick Chavaillon, Thierry Ponchon, Jean-Alain Chayvialle
Publikováno v:
Gastrointestinal Endoscopy. 55:342-347
Background: The present study was undertaken to identify factors affecting the severity of the duodenojejunal polyposis in patients with familial adenomatous polyposis. Methods: Duodenojejunal polyposis was evaluated in 41 consecutive patients with f
Autor:
J. Boulez, Bertrand Napoleon, Jean-Yves Scoazec, Françoise Berger, Christian Partensky, Géraldine Gouysse, Catherine Lombard-Bohas, Jérôme Dumortier, Alain Calender, Pierre-Jean Valette, Blandine Ligneau, Jean-Alain Chayvialle
Publikováno v:
The American Journal of Surgical Pathology. 25:752-760
Cystic endocrine tumors of the pancreas are rare and raise difficult clinical problems. Our aims were to reevaluate the diagnostic and therapeutic strategy and to assess their histopathologic characteristics. Thirteen cystic endocrine tumors diagnose
Autor:
Blandine Ligneau, Pierre-Jean Souquet, Isabelle Court-Fortune, C. Ardiet, Gilles Freyer, Paul Rebattu, Robert Riou, Véronique Trillet-Lenoir, Eric Morignat, Jean-Pierre Boissel, Pascal Girard, Brigitte Tranchand
Publikováno v:
Lung Cancer. 31:247-256
Purpose: To assess the potential relationships between systemic exposure to doxorubicin, etoposide and ifosfamide at first chemotherapy cycle and therapeutic effect, tumor response, toxicity, and survival, in small cell lung cancer (SCLC) patients. P
Publikováno v:
European Journal of Internal Medicine. 11:329-333
Background: The choice between supportive care or specific anticancer treatment for poor performance status (PS) breast cancer patients with multimetastatic disease and pancytopenia due to bone marrow involvement (BMI) often remains a clinical dilemm
Autor:
Blandine Ligneau, Véronique Trillet-Lenoir, Isabelle Court-Fortune, Robert Riou, Gilles Freyer, P. Rebattu, Pascal Girard, C. Ardiet, Pierre-Jean Souquet, Jean-Pierre Boissel, Brigitte Tranchand
Publikováno v:
British Journal of Clinical Pharmacology. 50:315-324
Aims To determine the population pharmacokinetic (PK) parameters of doxorubicin (Dox), etoposide (Eto) and ifosfamide (Ifo) in small cell lung cancer (SCLC) patients, to assess the potential relationship between those parameters and to estimate the i
Publikováno v:
Bulletin du cancer.
The therapeutic interest of gemcitabine both as a single drug and in combination is now well known and applied in various malignant diseases. However, it would be worth being further explored in two tumor models for which its efficacy has been suspec
Publikováno v:
Expert review of anticancer therapy. 1(2)
Metastatic colorectal cancer has long been considered as a short-term, poor prognosis, chemoresistant disease. Until the early 1990s, the impact of systemic chemotherapy on patient outcome was debated. Recently, the emergence of new therapeutic modal
Autor:
Christine, Clippe, Gilles, Freyer, Marie-Hélène, Bizollon, Daniel, Raudrant, François, Gilly, Danièle, Vitrey, Blandine, Ligneau, Véronique, Trillet-Lenoir
Publikováno v:
Bulletin du cancer. 89(4)
Primary peritoneal tumors are rare and yet not well-known malignancies. We report here the clinical cases of 8 patients who were referred to our institution with a primary peritoneal tumor, 4 serous carcinomas (PSC) and 4 malignant mesotheliomas (PMM
Autor:
Athanassios Iliadis, Isabelle Lochon, Pierre Canal, Gilles Freyer, Brigitte Tranchand, Véronique Trillet-Lenoir, Blandine Ligneau, C. Ardiet, Carole Amsellem, Etienne Chatelut
Publikováno v:
Cancer chemotherapy and pharmacology. 43(4)
Etoposide (VP16), a widely used anticancer drug, is a topoisomerase II inhibitor. A number of studies have highlighted a correlation between hematologic toxicity and pharmacokinetic or physiological parameters. Other studies have also suggested that
Publikováno v:
International journal of antimicrobial agents. 10(1)
Haematologic toxicity and its most frequent complication, febrile neutropenia represents the main limiting factor to the use of anti-cancer chemotherapy. The recent availability of recombinant human colony stimulating factors offers a new opportunity